Company: INSP
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001609550-25-000053
Chunk: 19

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 activities  Purchases of property and equipment(27,843)(32,096)Purchases of investments(177,375)(337,540)Proceeds from sales or maturities of investments248,700 252,753 Purchases of strategic investments(10,118)— Net cash provided by (used in) investing activities33,364 (116,883)Financing activities  Proceeds from the exercise of stock options8,962 23,359 Share repurchase of common stock(125,008)— Payment of taxes on net share settlement of equity awards(22,350)(9,045)Proceeds from issuance of common stock from employee stock purchase plan3,255 3,431 Net cash (used in) provided by financing activities(135,141)17,745 Effect of exchange rate on cash(35)48 Decrease in cash and cash equivalents(37,305)(38,025)Cash and cash equivalents at beginning of period150,150 185,537 Cash and cash equivalents at end of period$112,845 $147,512 Supplemental cash flow information  Cash paid for interest$15 $— Property and equipment included in accounts payable and accrued expenses$5,249 $3,456 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

9

Table of ContentsInspire Medical Systems, Inc.Notes to Consolidated Financial Statements (Unaudited) (Table amounts in thousands, except share and per share amounts)

1. Organization

Description of BusinessInspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first and only United States ("U.S.") Food and Drug Administration ("FDA"), European Union ("EU"), Medical Devices Regulation, and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. Inspire therapy received premarket approval from the FDA in 2014 and has been commercially available in certain European markets since 2011 and certain Asia Pacific markets since 2021.

2. Summary of Significant Accounting Policies

Basis of PresentationThe accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting and as required